Current market size is close to $1B annually and growing
Itch is #1 reason for canine veterinarian visits
have atopic dermatitis, an allergic skin disease
Key Profit Center
of dogs seen by dermatologists suffer from from pruritis (itch)
increase in itchy dog veterinarian visits since 2014
KindredBio is pursuing a multi-pronged approach toward atopic dermatitis.
KindredBio reported positive topline results from its pilot field effectiveness study of tirnovetmab (KIND-016), a fully caninized, high-affinity monoclonal antibody targeting interleukin-31, for the treatment of atopic dermatitis in dogs. Pivotal efficacy study commenced in the fourth quarter of 2020.
KindredBio unveiled positive results in a new long-acting interleukin-31 antibody program (KIND-039) that integrates the Company's novel half-life extension technology in April 2021. Results from the pharmacokinetic study of the molecule demonstrated that the fully caninized, high-affinity antibody has up to a three-fold longer half-life compared to tirnovetmab. This extended half-life is expected to allow for up to three-fold longer interval between dosing. KindredBio's half-life extension technology is intended to reduce dosing frequency, lower doses, and/or reduce cost of goods sold, while increasing pet owner convenience and compliance.
We reported positive results from our pilot laboratory study of our interleukin-4R molecule, including evidence of positive efficacy and dose response. The KIND-032 program is proceeding as expected with preparations underway for a pivotal study.
The company reported positive results from its pilot efficacy study of its canine IL-4/13 SINK molecule in the first quarter of 2020. An initial pilot study for IL-17 has also been completed and the molecule was well-tolerated. Both programs are currently on hold pending further funding or partnering capital.
“Itch associated with Atopic Dermatitis may be caused by either neurogenic, inflammatory and/or behavioral pathomechanisms. I often find that I need to address a combination of pathways to successfully control itch in my atopic patients.”